

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 3738

Title: Anti-EGFR therapies and metastatic colorectal cancer: current and future developments

Reviewer code: 00289406

Science editor: Gou, Su-Xin

Date sent for review: 2013-05-20 12:13

Date reviewed: 2013-05-20 16:49

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

There are several spelling errors in the script that need to be corrected. Otherwise a table with study results, effects and side effects would be helpful, however it might not be appropriate for an editorial article

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 3738

Title: Anti-EGFR therapies and metastatic colorectal cancer: current and future developments

Reviewer code: 02456377

Science editor: Gou, Su-Xin

Date sent for review: 2013-05-20 12:13

Date reviewed: 2013-07-15 21:42

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This paper summarized the efficacy and safety of anti-EGFR therapies (cetuximab or panitumumab) for colorectal cancer. Meanwhile, the author also discussed the efficacy of these therapies in conjunction with conventional chemotherapy. The conclusion was that the choice to use cetuximab or panitumumab in association with standard chemotherapy for mCRC according to patients fitness, acceptable toxicities profiles, survival outcome and mainly pharmaco-economic evaluation of those drugs in this setting.